StockTipsArenaBeta

BUY Morepen Laboratories Limited — Nirav Vora, JM Financial

BUYMorepen Laboratories Limited
Morepen Laboratories share price target & all analyst calls

byNirav Vora, JM FinancialHorizon: NA (inferred 1–3 months)6 Jul 2026via ET Now (Live)

Entry₹61.2Stated
Target₹70
Total upside +14.38% (call closed)
Stop lossNot given
Exit₹705 Aug 2026, 12:08 pm
Target hit+14.38%0.00%upside left
Follow Nirav Vora for new callsGet alertsWatch MOREPENLAB for new buy/sell callsGet alertsSee 74 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 5 Aug 2026
6 supporting3 neutral0 opposing
Supports the BUY call (6)

Morepen Labs Q1 Results: Stock hits 20% upper circuit as CDMO scale-up drives record earnings

NewsCnbc-Tv18·4 Aug · today

(opens in new tab)

Morepen Laboratories achieved its highest-ever quarterly revenue and earnings in Q1 FY27, with EBITDA growing 207% and PAT by 394%. The CDMO business has entered full-scale commercialization.

NSE · Press Release·4 Aug · today

(opens in new tab)

Morepen Laboratories reported highest-ever quarterly revenue and earnings in Q1'FY27. EBITDA grew by 207% and PAT by 394%. The company's CDMO mandate entered full-scale commercialization.

BSE · Company Update·4 Aug · today

(opens in new tab)

1 advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·30 Jul · 6d ago

Neutral / worth noting (3)

Morepen Laboratories Limited announced its un-audited financial results for the quarter ended June 30, 2026. The board also approved the record date for final dividend and extension for hiving off Med

NSE · Outcome of Board Meeting·4 Aug · today

(opens in new tab)

Morepen Laboratories Ltd has attached the financial results for the first quarter of the financial year 2027.

BSE · Board Meeting·4 Aug · today

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Morepen Laboratories

All analyst calls on Morepen Laboratories

More from Nirav Vora, JM Financial

Every call and its outcome